Erschienen in:
01.01.2016 | Melanomas
Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity
verfasst von:
Edmund K. Bartlett, MD, Madalyn G. Peters, MD, Anne Blair, MS, Mark S. Etherington, MD, David E. Elder, MB, ChB, Xiaowei G. Xu, MD, DuPont Guerry, MD, Michael E. Ming, MD, MSCE, Douglas L. Fraker, MD, Brian J. Czerniecki, MD, PhD, Phyllis A. Gimotty, PhD, Giorgos C. Karakousis, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2016
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Sentinel lymph node (SLN) biopsy is recommended for all patients with intermediate-thickness melanomas. We sought to identify such patients at low risk of SLN positivity.
Methods
All patients with intermediate-thickness melanomas (1.01–4 mm) undergoing SLN biopsy at a single institution from 1995–2011 were included in this retrospective cohort study. Univariate and multivariate logistic regression determined factors associated with a low risk of SLN positivity. Classification and regression tree (CART) analysis was used to stratify groups based on risk of positivity.
Results
Of the 952 study patients, 157 (16.5 %) had a positive SLN. In the multivariate analysis, thickness <1.5 mm (odds ratio [OR] 0.29), age ≥60 (OR 0.69), present tumor-infiltrating lymphocytes (OR 0.60), absent lymphovascular invasion (OR 0.46), and absent satellitosis (OR 0.44) were significantly associated with a low risk of SLN positivity. CART analysis identified thickness of 1.5 mm as the primary cut point for risk of SLN metastasis. Patients with a thickness of <1.5 mm represented 36 % of the total cohort and had a SLN positivity rate of 6.6 % (95 % confidence interval 3.8–9.4 %). In patients with melanomas <1.5 mm in thickness, the presence of additional low risk factors identified 257 patients (75 % of patients with <1.5 mm melanomas) in which the rate of SLN positivity was <5 %.
Conclusions
Despite a SLN positivity rate of 16.5 % overall, substantial heterogeneity of risk exists among patients with intermediate-thickness melanoma. Most patients with melanoma between 1.01 and 1.5 mm have a risk of SLN positivity similar to that in patients with thin melanomas.